Grassley, Chuck: Good morning. Welcome, everybody. Before I get to the agenda, I'd like to address this week's Arctic Frost hearing. First, this committee is not going to give in to the Democrats' ill-advised strategy to bring Jack Smith in before our investigative record is entirely ready. Kim Strassel of the Wall Street Journal had this to say about my recent document production. The facts to roll out about Jack Smith, quote, those facts are getting uglier, end of quote. Second, my Democrat colleagues in the partisan media continue to sing a sob story about fired partisan DOJ and FBI personnel, so I want to take this opportunity to remind my colleagues that many of the fired personnel retaliated against my whistleblowers during the Biden administration, and then I didn't hear a single peep from my Democrat colleagues then about uh these whistleblowers' lives being upended and destroyed, and I believe part of the 16 people that I helped get justice in the last year were some of these personnel. Not all of those people wanted their jobs back, but they wanted their national security clearance, they wanted back pay, and some of them wanted their jobs back and got their jobs back, but when their lives were being upended, I never heard anything from the other side. Third and lastly, this committee today is investigating government weaponization because my Democrat colleagues didn't lift a finger during the Biden administration. These were four years of uninterrupted, consistent, and sustained political attacks on Republicans by the previous administration. This committee's work exposing that political corruption will continue. Uh now to today's agenda, we have three bills and two nominations. Brian Guttgen, Marshall, Montana. James Stewart, Marshall, Minnesota. We'll also vote on three H.R. 2159, Count the Crimes to Cut Act, and Protecting Americans from Russian Litigation Act of 2025. And I think that we have things working. bills. I want to take a moment to talk about the Combating Illicit Zylozyne Act, which I led with Senator Cortez Masto, and I want to thank her for taking the lead on that. We began considering this important bill last week, and I hope to complete the committee's work on that bill today. Our bill simply classifies this highly toxic drug as Schedule 3 under the Controlled Substance Act while protecting its legitimate use for agriculture by veterinarians serving farmers and ranchers. I explained last week that this critical and emphasized bipartisan legislation has a wide range of support from law enforcement, the agriculture community, and from the victims. It's been a priority of both Biden and the Trump administrations, and it's co-sponsored by 14 Democrats and 18 Republicans. We heard the tragic stories of families devastated by this poison last week. We're here today for those same families. Last week, it became clear that the committee needed a few additional works to clarify language. We want to ensure that our bill solves an important problem while also promoting transparency. We've taken the last seven days to work with members on both sides of the aisle to reach an language. This new language is explicit about what documents we expect to be produced by HHS and by DEA. My staff and I engaged multiple offices on both sides of the aisle, and we did it in good faith, and I think we had the same good faith from the people we were talking to. And I was glad to work with Senators Whitehouse, Coons, and now Senator Booker on a revised manager's amendment that I think achieves the right balance. I want to be crystal clear, however, about the intent of this manager's amendment. This bill requires the Department of Health and Human Services to submit their scientific and medical evaluation and scheduling recommendations for xylosine. They will submit this along with the DEA's law enforcement, DEA's regulatory, and DEA's abuse evaluation in a combined public and prompt report to Congress. This way, the information available to the public will closely mimic the data that would have been published in the Federal Register if xylosine was administratively scheduled. And I told you last week why the legislation was necessary, because by regulation, they couldn't protect the legal use by veterinarians of this product. It's important for the American people to see drug scheduling information from both the DEA and HHS, because that is how Congress intended that process to work. Congress granted DEA the authority to schedule drugs in consultation with the Secretary of HHS. Now, the important point. If the HHS scientific and medical evaluation was released alone, it would not provide the public with a complete picture, because it is just one part of the administrative process. So the manager's amendment will release this information, because in its proper context, with the confined views of the two relevant agencies, the committee wants to see the from HHS. I want to see it, but I also want to see the analysis of the Drug Enforcement Agency, which is the other half of the equation. That's what the manager's amendment does that I called up last week, and that's what the new language now spells out with absolute clarity. Senator Dorgan.